Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.67 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.67 |
| ▸ | TUBB | P07437 | 4/20 | 0.67 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.67 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.67 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.67 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.67 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.67 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.67 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.67 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.67 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.67 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.67 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.67 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.67 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.67 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12370775 | 0.97 | NPC1 (0.66) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL11990784 | 0.95 | NPC1 (0.66) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL11990785 | 0.95 | NPC1 (0.66) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL15188850 | 0.95 | NPC1 (0.66) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL14554057 | 0.95 | NPC1 (0.66) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL22895088 | 0.95 | NPC1 (0.70) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL15256718 | 0.95 | NPC1 (0.66) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL15147360 | 0.95 | NPC1 (0.64) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL16219995 | 0.94 | NPC1 (0.70) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL16079222 | 0.94 | NPC1 (0.64) | NPC1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140274947-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2012088391-A1 | NON-RING HYDROXY SUBSTITUTED TAXANES AND METHODS FOR SYNTHESIZING THE SAME | NEKTAR THERAPEUTICS (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | NPC1 372/4885TUBB4A 102/4885TUBB 40/4885 |
| US-20140274947-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | NPC1 372/4885TUBB4A 102/4885TUBB 40/4885 |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | NPC1 531/4885TUBB4A 1258/4885TUBB 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.